The TissueCypher® Barrett’s Esophagus Assay identifies patients with Barrett’s esophagus that progress to esophageal cancer at a rate 5 to 10 times higher than the current standard of care. TissueCypher® delivers the holy grail of Barrett’s esophagus: predicting progression and non-progression.